Current Report Filing (8-k)
September 26 2018 - 5:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 26, 2018
Vaccinex, Inc.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-38624
|
|
16-1603202
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
1895 Mount Hope Avenue
Rochester, New York
|
|
14620
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(585)
271-2700
(Registrants telephone number, including area code)
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☒
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01
|
Regulation FD Disclosure.
|
On September 26, 2018, Vaccinex, Inc. (the Company) made available a presentation that it intends to utilize in connection with investor
meetings. The presentation is attached as Exhibit 99.1 to this Current Report on Form
8-K.
This information
included as part of this Current Report on Form
8-K
is furnished pursuant to Item 7.01 of Form
8-K
and shall not be deemed to be filed for the purposes of
Section 18 of the Securities Exchange Act of 1934 (Exchange Act), as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933,
as amended, or the Exchange Act, whether made before or after the date of this report, except as shall be expressly set forth by specific reference in such filing.
Item 9.01
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
VACCINEX, INC.
|
|
|
|
|
Date: September 26, 2018
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Scott E. Royer
|
|
|
|
|
|
|
Scott E. Royer
|
|
|
|
|
|
|
Chief Financial Officer
|
Vaccinex (NASDAQ:VCNX)
Historical Stock Chart
From Apr 2024 to May 2024
Vaccinex (NASDAQ:VCNX)
Historical Stock Chart
From May 2023 to May 2024